Navigation Links
Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting

>A nerve cell has one extension, called an axon, which it uses to communicate via electrical signals to other nerve cells. All but the smallest axons have a special covering of a fatty substance called myelin that acts as insulation to preserve and speed these nerve signals, much like the insulating cover of an electrical cord helps preserve the transmission of electricity.

In MS, the myelin becomes damaged and the axon cannot effectively transmit electrical impulses. Specifically, the damaged myelin exposes channels in the membrane of the axon, which allow potassium ions to leak from the axon, dissipating the electrical current. Fampridine-SR blocks these exposed channels, and helps the electrical signals to pass through areas of damage.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these s
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acorda Therapeutics Presents Fampridine Data ACTRIMS Meeting
(Date:7/14/2014)... 14, 2014  Celsion Corporation (NASDAQ: CLSN ), ... Company will ring the NASDAQ Stock Market closing bell on ... York, NY . President and CEO ... and EGEN management teams will participate in the closing bell ... live webcast will be available at https://new.livestream.com/nasdaq/live .  ...
(Date:7/14/2014)... SAN ANTONIO , July 14, 2014 /PRNewswire/ ... prodrug therapeutics for the treatment of cancer, announces ... S. Traube , has issued the following research ... Sheldon S. Traube , Director of Research, Kareg ... Read the full report: ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
Breaking Medicine Technology:Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 2Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3
... attacks highlighted in new study ... global health outcomes meeting, ATHENS, Greece, Nov. 9 ... patients,prevention of recurrent heart attacks continues to be a major ... non-fatal heart,attack within the first three months of hospitalization for ...
... from an investigational,open-label, randomized study assessing extended ... anemia in subjects with Stages 3 - ... at the American Society,of Nephrology 41st Annual ... the FDA-approved,three-times-per-week (TIW) regimen, plus once-a-week (QW) ...
Cached Medicine Technology:Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death 2Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death 3Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6
(Date:7/14/2014)... The Encino cosmetic dentist at ... and porcelain veneers. These restorations are an excellent ... and greater loss of healthy tooth tissue. They work ... flaws on the tooth. Encino dentist Dr. Mastour and ... ensure they offer the most appropriate treatment recommendations for ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July ... linked to multiple health issues, but dementia isn,t one of ... widowhood may even delay dementia, the researchers found. "For ... was associated with a later age of developing full-blown dementia ... Bryan Woodruff. Woodruff, an assistant professor of neurology ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... based on computerized simulation models suggests that the lifetime risk ... tomography (CT scan) coronary angiography varies widely, with the risk ... disease (CAD) is the leading cause of death in men ... 5 deaths, and a major cause of health care expenditures, ...
... reveals abnormal cells the woman will be offered colposcopy, ... cervix with a special microscope. Many women find the ... of anxiety before and during colposcopy. ,,Researchers ... trials that involved a total of 1441 women and ...
... The U.S. Food and Drug Administration (FDA) has approved the ... degenerative disc disease , one of the most common causes ... approved, the Prestige Cervical Disc, is manufactured by Medtronic Sofamor ... disc means that people with cervical degenerative disc disease now ...
... law to curb smoking to secure peoples' rights to the ... much committed towards implementing a comprehensive anti-tobacco law to reduce ... children and adolescents," Ali bin Shukur, Under-secretary of the Ministry ... ,A draft bill on smoking is being deliberated at ...
... of researchers have found that combining pre-operative chemotherapy and ... six percent when compared with surgery alone. ... the MRC Clinical Trials Unit in London after they ... from seven of these trials were available from trial ...
... a plan for coping with a pandemic flu outbreak, the ... disease outbreak and track its progress across the country. ... the borders if a pandemic flu outbreak occurs somewhere in ... president for biodefense:The reality is that there are tremendous challenges ...
Cached Medicine News:Health News:CT Scan Radiations may Lead to Cancer 2Health News:FDA Approves First Artificial Cervical Disc 2Health News:Chemotherapy Better for Non Small Cell Lung cancer 2Health News:Americas Preparations For Flu Outbreak Still Incomplete 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: